In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Israeli biotech Sol-Gel nets $80.2mm in Nasdaq IPO

Executive Summary

Five months after filing, dermatology-focused Israeli biotech Sol-Gel Technologies Ltd. (topical drug therapies) netted $80.2mm in a Nasdaq initial public offering of 7.2mm ordinary shares, including the overallotment, at $12. It had originally planned to offer 5mm shares at an $11-13 range.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies